NCT01903681View on ClinicalTrials.gov

Assessment of the Pharmacokinetics of Circadin® in Children With Neurodevelopmental Disorders and Sleep Disturbances

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

February 28, 2014

Study Completion Date

April 30, 2014

Conditions
Sleep Problems
Interventions
DRUG

Circadin 2 mg

First arm lower dose

DRUG

Circadin 10 mg

Second arm higher dose

Trial Locations (1)

2333

Centre for Human Drug Research, Leiden

Sponsors
All Listed Sponsors
lead

Neurim Pharmaceuticals Ltd.

INDUSTRY

NCT01903681 - Assessment of the Pharmacokinetics of Circadin® in Children With Neurodevelopmental Disorders and Sleep Disturbances | Biotech Hunter | Biotech Hunter